Arecor advancing today’s therapies to enable healthier lives


  • Arecor uses its ground-breaking technology platform, Arestat™ to develop future medicines from existing therapies, across all disease indications and at any stage of a drug lifecycle
  • Proprietary portfolio includes first franchise in diabetes and has expanded its development pipeline into anti-infectives
  • Partners with leading pharmaceutical and biotech companies to improve their products, find solutions or create next-generation products
Arecor -

What Arecor does

Arecor Limited, a private biopharmaceutical company, is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapies using its proprietary Arestat technology.  

Arestat is a world leading, innovative formulation technology platform which significantly enhances the properties of therapeutic proteins and peptides and has the unique potential to deliver superior formulations of both new and existing products which would otherwise not be possible.

It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.

Inflexion points

In June, the company presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, to the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting. 

It said the next step will be to explore AT247’s potential as the ideal insulin for use in a pump and fully closed-loop delivery (artificial pancreas) systems.

In March, Arecor extended a multi-product collaboration with a US-based biotech company to develop products for oncology and a rare genetic orphan condition.

Under the collaboration, Arecor said it will leverage its Arestat technology to develop liquid formulations of two proprietary novel products, while its partner is currently funding the development work and has an option to acquire the formulations and associated intellectual property under separate milestone-bearing licenses at pre-agreed financial terms.

In February, the firm inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.

The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.

Later that month, the company said it had achieved an important second, contractual milestone with one of its pharmaceutical partners.

The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.

In accordance with the license agreement, the partner has rights to further develop, manufacture and commercialise a novel, superior formulation of a biosimilar product, which was developed by Arecor using its proprietary Arestat platform. 

In January, Arecor also signed an agreement with FTSE 100 firm Hikma Pharmaceuticals PLC (LON:HIK) to develop a new, ready-to-use injectable medicine.

The new product, to be announced prior to launch, will use Arecor’s Arestat drug formulation technology and is expected to be submitted to the US Food and Drug Administration for regulatory approval in 2021.

In December, Arecor hailed the successful completion of a phase I trial for its ultra-rapid acting insulin for diabetics, which it said had a “favourable profile” when compared with standard treatments.

The company said that its candidate, AT247, had finished a phase I double-blind, randomised study at The Medical University of Graz and Joanneum Research in Austria, in which it was measured against two other insulins on the market, NovoRapid and Fiasp.


What the boss says - Sarah Howell

“The successful completion of our AT247 Phase I clinical study and selection for an oral presentation at ADA is an important landmark for Arecor.  AT247 is under development as an ultra-rapid acting insulin targeted at improving treatment and healthcare outcomes for people living with Type I diabetes.  In addition to the potential to improve post prandial blood glucose control, AT247 may play a critical role in advancing artificial pancreas systems.  With AT247’s favourable profile over current treatments, we believe that our product has the potential to advance the diabetes treatment landscape.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

5 days, 8 hours ago

3 min read